Hyloris announces approval of new drug for pain management
pharmafile | October 19, 2021 | News story | Manufacturing and Production |
Specialist biopharma company Hyloris has announced the further extension of the European footprint of Maxigesic® IV, which is a novel combination of 1000mg paracetamol and 300mg ibuprofen, for the treatment of post-operative pain.
Maxigesic IV provides a non-opioid, dual-mode-of-action pain management alternative to traditional analgesics. It has now obtained regulatory approval in 27 countries. Kensington Pharmaceuticals Ltd, the distributor for the UK, and Jed Pharma Ltd, the distributor in Ireland, are now preparing for commerce sales in early 2022.
Belgium-based Hyloris Pharmaceuticals is committed to addressing unmet medical needs through reinventing existing medications. The company has a broad pipeline of 13 reformulated and repurposed value-added medicines that have the potential to offer advantages over existing medications.
The company also has 3 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and the new Maxigesic IV.
Speaking of the approval of Maxigesic IV, Stijn Van Rompay, CEO of Hyloris, commented: “Maxigesic IV is a breakthrough non-opioid pain treatment, offering surgeons a well-tolerated and effective alternative to highly addictive opioids. We are very pleased that Maxigesic IV is gaining further momentum with additional regulatory approvals and together with our partners, we look forward to making the product available in these key markets.”
Maxigesic IV has been developed under the strategic partnership between Hyloris and AFT Pharmaceuticals, formed in 2012. The product is now licensed in over 100 countries across the globe, and is now launched in 5 countries. It is protected by several granted patents and pending patent applications.
Lina Adams
